Core Insights - Voyager Therapeutics is focusing on 2025 as the "year of tau," with two key assets targeting tau-related conditions [2] - The company anticipates tau PET imaging data from a multiple ascending dose study by the end of the year [2] - A gene therapy asset aimed at tau knockdown, similar to BIIB080, is expected to have significant readouts in the mid-year timeframe [2] Group 1 - The first asset is a C-terminal antibody targeting tau, with imaging data expected soon [2] - The second asset is a gene therapy for tau knockdown, which is part of the company's broader strategy [2] - Voyager is introducing newly discovered blood-brain barrier (BBB) penetrant capsids into clinical trials for the first time this year [3] Group 2 - The company has two assets utilizing these capsids: the tau knockdown gene therapy and a partnered program for Friedreich's ataxia [3] - Voyager aims to establish proof of concept for the efficacy of its capsids in producing gene expression [3]

PresentationPaul MatteisStifel, Nicolaus & Company, Incorporated, Research Division Great. Thanks very much. This is going to be an interesting 45-minute discussion on a number of topics within the Biogen pipeline. With me is Diana Gallagher, Head of Clinical Development; and Stephanie Fradette, Head of the Neuromuscular Development Unit. Maybe just you can each of you just sort of briefly introduce yourselves, how long you've been at Biogen, and then we can get right into it. I think I wanted to start with ...

Prothena Corporation FY Conference Summary Company Overview - **Company**: Prothena Corporation (NasdaqGS:PRTA) - **Focus**: Expertise in protein dysregulation with a robust pipeline in neurodegenerative diseases, including Alzheimer's, Parkinson's, and ATTR cardiomyopathy [2][22] Key Programs and Developments - **Phase 3 Programs**: - **Prasunezumab**: Targeting early Parkinson's disease in collaboration with Roche, expected to initiate in Q4 2025 [2][22] - **Coramitug**: Targeting ATTR cardiomyopathy in collaboration with Novo, which has already initiated Phase 3 [2][22] - **Phase 2 Program**: - **PRX019**: Targeting tau in Alzheimer's disease, partnered with Bristol Myers Squibb [2][22] - **Phase 1 Program**: - **PRX012**: An undisclosed target for neurodegeneration, also partnered with Bristol [2][22] Financial Outlook - Prothena anticipates earning up to **$105 million** in clinical milestones in 2026 related to coramitug and PRX019 [2][22] Shareholder Actions - Recently approved a share repurchase program for 2026 to support distributable reserves [2][22] Pipeline Insights - **Alzheimer's Program**: The company is exploring partnerships to advance its amyloid beta program, emphasizing the importance of collaboration for cost efficiency and bandwidth [4][5] - **Transferrin Technology**: Prothena is developing PRX012, which incorporates transferrin technology to enhance blood-brain barrier penetration. Preclinical data is expected in 2026 [7][17][18] Clinical Data and Efficacy - **Amyloid Reduction**: Over **80%** of patients treated with the amyloid beta molecule are reported to be amyloid negative after 18 months [5][6] - **ARIA Rates**: Reported around **40%** for the amyloid beta treatment, with ongoing efforts to mitigate these effects [6][7] - **Coramitug Data**: Recent presentations showed a **50%** difference from placebo in NT-proBNP levels, supporting the move to Phase 3 [24][25] Collaborations and Partnerships - Prothena has established strong collaborations with Roche, Novo, and Bristol Myers Squibb, focusing on scientific dialogue and clinical decision-making [22][26] - The company is actively supporting partner programs as they transition into Phase 3 [26] Regulatory Considerations - The company is preparing for potential IND submissions, with ongoing discussions with the FDA regarding preclinical toxicology requirements [8][9] Market Position and Future Directions - Prothena is positioning itself to leverage its unique constructs in the competitive landscape of Alzheimer's treatments, particularly with its transferrin-based technology [17][40] - The company is closely monitoring developments in the field, including Eli Lilly's studies, to inform its strategic direction [5][40] Conclusion - Prothena Corporation is advancing multiple promising programs in neurodegenerative diseases, with a strong focus on collaboration and innovative technologies to enhance treatment efficacy and patient outcomes [2][22][40]